Dyne Therapeutics股价暴跌23%，尽管即将公布长期临床数据
· rttnews.com
Dyne Therapeutics Inc.（DYN）股价周二报18.60美元，下跌5.68美元，跌幅23.39%，尽管该公司宣布计划公布其1/2期ACHIEVE试验中zeleciment basivarsen用于治疗1型强直性肌营养不良症（DM1）的额外一年临床数据。
Dyne Therapeutics Inc. (DYN) shares are currently trading at $18.60, down $5.68, or 23.39 percent on Tuesday, despite the company announcing plans to present ad...